By Counterforce Health Team in Brineura (cerliponase alfa) —

How to Get Brineura (Cerliponase Alfa) Covered by Cigna in California: Complete PA Guide and Appeals Process

Answer Box: Getting Brineura Covered by Cigna in California

Cigna requires prior authorization (PA) for Brineura (cerliponase alfa) for patients ≥3 years with confirmed CLN2 disease. Submit PA via Cigna provider portal or Express Scripts with TPP1 enzyme/genetic testing, neurologist consultation, and baseline motor assessments. If denied, file internal appeal within 180 days, then California's Independent Medical Review (IMR) through DMHC for binding external review. Success rates for rare disease appeals like Brineura reach 55-70% at IMR level.

Start today: Contact your child's neurologist to gather CLN2 diagnostic confirmation and begin PA submission 2-3 weeks before planned treatment.

Table of Contents

  1. Cigna's Coverage Policy for Brineura
  2. Medical Necessity Requirements
  3. Step Therapy and Exceptions
  4. Quantity and Frequency Limits
  5. Required Diagnostic Testing
  6. Site of Care Requirements
  7. Clinical Evidence Guidelines
  8. Step-by-Step: Fastest Path to Approval
  9. Common Denial Reasons & Solutions
  10. California Appeals Process
  11. Costs and Patient Support
  12. FAQ

Cigna's Coverage Policy for Brineura

Cigna classifies Brineura (cerliponase alfa) as a specialty medication requiring prior authorization across all plan types—HMO, PPO, and Medicare Advantage. The drug is typically managed through Express Scripts/Accredo specialty pharmacy, with coverage decisions based on FDA labeling and medical necessity criteria.

Plan Coverage Variations:

  • Commercial plans: Standard PA requirements with 180-day internal appeal window
  • Medicare Advantage: Enhanced appeal rights with expedited pathways for urgent cases
  • Medicaid managed plans: Follow state Medicaid guidelines with additional protections

Initial approval lasts 12 months, with reauthorization requiring documentation of clinical benefit and tolerability.

Medical Necessity Requirements

Core Eligibility Criteria

Cigna's medical necessity criteria align with FDA labeling for Brineura:

Requirement Documentation Needed Source
Age ≥3 years old Birth certificate, medical records
Diagnosis Confirmed CLN2 disease (TPP1 deficiency) Enzyme activity testing + genetic confirmation
Prescriber Pediatric neurologist or specialist Provider credentials, consultation notes
Baseline Assessment Motor function evaluation using CLN2 Clinical Rating Scale Neurological assessment scores

Diagnostic Confirmation Requirements

CLN2 disease diagnosis must be confirmed through:

Primary Testing:

  • TPP1 enzyme activity: Deficient levels in leukocytes or fibroblasts (gold standard)
  • Genetic testing: Two pathogenic variants in CLN2/TPP1 gene

Alternative Screening:

  • Dried blood spot (DBS) enzyme assays for initial screening
  • Saliva testing (when blood/tissue unavailable)

Common mutations include c.509-1G>C and c.622C>T, present in up to 89% of patients. Mayo Clinic offers comprehensive leukocyte testing panels for CLN1/CLN2 differential diagnosis.

Step Therapy and Exceptions

Good news: Cigna does not typically require step therapy for Brineura since no alternative disease-modifying treatments exist for CLN2 disease. However, documentation of inadequate symptom control with supportive care may strengthen your case.

Medical Exception Pathways

If step therapy is imposed:

  • Contraindication: Document medical reasons other treatments cannot be used
  • Treatment failure: Show inadequate response to supportive seizure/symptom management
  • Intolerance: Demonstrate adverse effects from alternative approaches

Quantity and Frequency Limits

Cigna follows FDA-approved dosing:

  • Standard dose: 300 mg every 14 days via intraventricular infusion
  • Quantity limits: 1 kit (2 vials, 300 billable units) per 14-day period
  • No titration: Fixed dosing per FDA labeling

Renewal Requirements

Annual reauthorization requires:

  • Updated CLN2 Clinical Rating Scale assessments (every 6 months)
  • Documentation of continued benefit (slowed motor decline)
  • Safety monitoring results (brain MRI, infection surveillance)
  • Ongoing neurologist supervision

Required Diagnostic Testing

Pre-Authorization Testing

Before PA submission, ensure you have:

Essential Labs:

  • TPP1 enzyme activity results (deficient levels)
  • Genetic testing confirming CLN2 mutations
  • Baseline CLN2 Clinical Rating Scale (motor domain ≥1)

Additional Assessments:

  • Cardiac evaluation (ECG within 6 months)
  • Brain MRI baseline
  • Assessment of intraventricular device candidacy

Timing Requirements: Testing should be recent (within 6 months) and clearly demonstrate CLN2 diagnosis with symptomatic disease.

Site of Care Requirements

Brineura requires specialized administration that standard infusion centers cannot provide:

Facility Requirements

Must have:

  • Capability for intraventricular access via surgically implanted reservoir
  • Equipment for hypersensitivity management (including anaphylaxis)
  • CPR support and emergency response capabilities
  • Sterile infusion environment with aseptic technique protocols

Cannot be administered:

  • At home
  • In standard outpatient infusion centers
  • Without specialized neurosurgical device access

Administration Process

  1. Device implantation: 5-7 days before first infusion
  2. Pre-medication: Antihistamines ± antipyretics/corticosteroids 30-60 minutes prior
  3. Infusion time: ~4.5 hours total (300 mg Brineura + electrolyte flush)
  4. Monitoring: Continuous observation for device complications and hypersensitivity

Contact BioMarin ACCESS 360° for site locator assistance and payer-specific guidance.

Clinical Evidence Guidelines

Supporting Medical Literature

When building your medical necessity case, include:

FDA Approval Evidence:

  • Pivotal trial data: Non-randomized study showing slowed motor function decline
  • FDA labeling confirming safety and efficacy in pediatric patients ≥3 years

Clinical Guidelines:

  • No specific American Academy of Neurology guidelines exist yet
  • Payer medical policies (e.g., South Carolina Blues) recognize medical necessity with neurologist consultation

Key Clinical Points:

  • Brineura is the only FDA-approved disease-modifying therapy for CLN2
  • Natural history shows rapid neurologic decline without treatment
  • Early intervention provides greatest benefit

Step-by-Step: Fastest Path to Approval

Week 1-2: Gather Documentation

  1. Neurologist consultation: Confirm CLN2 diagnosis and treatment candidacy
  2. Collect test results: TPP1 enzyme activity and genetic testing
  3. Baseline assessments: CLN2 Clinical Rating Scale, cardiac evaluation

Week 3: Submit Prior Authorization

  1. PA submission: Via Cigna provider portal or Express Scripts
  2. Include all documentation: Diagnosis confirmation, prescriber rationale, facility verification
  3. Track status: Check portal every 2-3 days; standard response in 5 business days

If Approved: Treatment Planning

  1. Device placement: Schedule neurosurgical consultation for intraventricular reservoir
  2. First infusion: Coordinate with approved facility 5-7 days post-device placement
Tip: Submit PA 2-3 weeks before planned treatment start to allow for potential appeals.

Common Denial Reasons & Solutions

Denial Reason Solution Strategy Required Documentation
"Not medically necessary" Cite natural history of CLN2 progression NEJM studies, FDA label, neurologist attestation
Age criteria not met Confirm ≥3 years per FDA labeling Birth certificate, current medical records
Inadequate diagnosis Provide comprehensive CLN2 confirmation Both enzyme and genetic testing results
Facility/site concerns Verify approved infusion center Network confirmation, facility capabilities
Non-formulary status Request formulary exception Medical necessity letter citing no alternatives

Sample Medical Necessity Language

"Patient has confirmed CLN2 disease with deficient TPP1 enzyme activity and biallelic pathogenic CLN2 mutations. Brineura is the only FDA-approved disease-modifying therapy for this progressive neurologic condition. Without treatment, natural history demonstrates rapid motor decline and loss of ambulation. Early intervention with Brineura has been shown to slow this progression in the pivotal FDA trial."

California Appeals Process

California offers robust appeal protections through dual regulatory oversight:

Internal Appeals with Cigna

Timeline: 180 days from denial to file Process:

  • Standard review: 30 days for decision
  • Expedited review: 72 hours for urgent cases (CLN2 qualifies)
  • Submit via member portal or mail with all supporting documentation

Independent Medical Review (IMR)

After internal appeal denial, California's IMR provides binding external review:

Eligibility: Available after internal appeal or 30-day delay Success rates: 55-70% overturn rate for rare disease cases like Brineura Timeline:

  • Standard: 45 days
  • Expedited: 7 days (often within 72 hours for progressive conditions)

How to File IMR:

  1. Online: dmhc.ca.gov (no fee)
  2. Phone: 888-466-2219 for assistance
  3. Required documents: Denial notice, medical records, peer-reviewed studies, plan policy rebuttals
Note: California fined UnitedHealthcare $475,000 for delays/denials, strengthening rare disease appeal leverage.

When to Escalate

For additional support:

  • DMHC Help Center: 888-466-2219 for HMO/managed care plans
  • CA Department of Insurance: 800-927-4357 for PPO plans
  • Health Consumer Alliance: Independent consumer assistance

Costs and Patient Support

Financial Assistance Options

Manufacturer Support:

  • BioMarin ACCESS 360°: Hub services, copay assistance, appeals support
  • Patient assistance programs for uninsured/underinsured

Foundation Resources:

  • Batten Disease Support and Research Association
  • National Organization for Rare Disorders (NORD)
  • HealthWell Foundation (verify current CLN2 fund availability)

Cost Considerations

Public list pricing: ~$27,000 per biweekly infusion ($702,000 annually), plus facility and procedure costs. Negotiated insurance rates vary significantly.

Counterforce Health specializes in turning insurance denials into targeted, evidence-backed appeals for complex medications like Brineura. Our platform analyzes denial letters and plan policies to draft point-by-point rebuttals aligned with payer criteria, incorporating the right clinical evidence and procedural requirements. For families navigating Cigna's prior authorization process for Brineura, Counterforce Health provides time-saving templates and expert guidance to improve approval odds and reduce back-and-forth with insurers.

FAQ

How long does Cigna PA take for Brineura in California? Standard response is 5 business days; expedited requests for urgent cases receive 72-hour turnaround per Cigna policy.

What if Brineura is non-formulary on my Cigna plan? Request formulary exception through Express Scripts with medical necessity documentation. No equivalent CLN2 treatments exist, strengthening exception requests.

Can I request expedited appeal for CLN2 disease? Yes. CLN2 qualifies as progressive neurologic condition warranting expedited review (72 hours internal, 7 days IMR) in California.

Does step therapy apply if my child failed treatments in another state? Generally no step therapy required for Brineura, but document prior supportive care attempts regardless of location.

What documents do I need for California IMR? Denial letter, complete medical records, CLN2 diagnostic testing, neurologist notes, peer-reviewed studies, and plan policy rebuttals.

How much does Brineura cost with Cigna coverage? Varies by plan; specialty tier copays typically range $100-500+ per infusion. BioMarin copay assistance may reduce out-of-pocket costs.

Can I get Brineura at any infusion center? No. Requires specialized facility with intraventricular access capabilities, sterile environment, and emergency response equipment.

What's the success rate for Brineura appeals in California? California IMR shows 55-70% overturn rates for rare disease denials when proper medical evidence is provided.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Insurance coverage decisions involve complex medical and policy considerations. Always consult with your healthcare provider and insurance plan directly for specific coverage determinations. For additional help with appeals in California, contact the DMHC Help Center at 888-466-2219.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.